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4EXECUTIVE SUMMARY
This is a Communication to the Council and the European Parliament on the need for
accelerated action targeted at major communicable diseases within the context of poverty
reduction. It explains the issue of communicable diseases as a burden on the poorest and an
obstacle to development, analyses the major policy issues involved, reports on the rationale for
continuous Community involvement, and sets out a framework with three broad areas for
targeted action.
Communicable diseases: a burden on the poorest and an obstacle to development
Investments in health can make a major contribution to poverty reduction and economic
growth. In developing countries, communicable diseases, particularly HIV/AIDS, malaria and
tuberculosis continue to limit human development. World wide, these three diseases cause the
deaths of more than five million people each year with the greatest impact on morbidity and life
expectancy in developing countries.
The failure to reduce the burden from these diseases and evidence of their increasing impact
has brought them to the centre of the development debate and has led to calls for urgent action
and a series of international initiatives.
The Commission has made a commitment to support an accelerated response against what has
become a global emergency. There is a need for additional selective and targeted approaches to
complement long standing and ongoing Community support to strengthen health systems to
deliver services that benefit the poor.
The rationale for accelerated European Community action
The goal of the new EC Development Policy is poverty reduction. One of the priority areas for
EC development aid is the support to macroeconomic policies in developing countries with an
explicit link with poverty reduction strategies, in particular sector programmes in social areas
(health, education) 1. The European Community has an unique mandate to do so, being able to
coherently address humanitarian, development, trade, health, education and research issues.
Since 1990, Community investment in Health, AIDS and Population (HAP) assistance has
reached more than 100 developing countries through a variety of complementary instruments
for a total amount of Euro 3.4 billion. The Commission will strengthen its support to the health
sector in developing countries, and calls for complementary actions in the areas of optimising
impact, affordability and investment in research and development. Focus on disease prevention,
promotion of health and improved health systems shall remain the EC´s main long-term
response in improving health and reducing poverty in developing countries.
The Commission has become increasingly active in the international debate to increase
developing countries’ access to affordable key pharmaceutical products. This has involved
extensive consultation and review of multiple issues including; infrastructure, financing
mechanisms, international pricing and licensing mechanisms, intellectual property rights, tariffs
                                               
1 COM (2000) 212, p. 25.
5and appropriate incentives to increase investment in global health, including key
pharmaceuticals2.
In addition, Europe can build upon a long-standing tradition of excellence in communicable
disease surveillance and control and in health research. European industry produces more than
60% of the vaccines used in developing countries and is among the largest producers of anti-
infective drugs. The Community has increased investment in particular in communicable
disease research over recent years, and plays an important role in facilitating new public–
private partnerships for research and development of drugs and vaccines that are of particular
importance to the health of people in developing countries.
A framework for Community action should contain three broad areas for targeted
action.
1. Reaching optimal impact of existing interventions, services and commodities
targeted at the major communicable diseases affecting the poorest populations.
The major communicable diseases are, in principle, largely preventable/and or readily treatable
using existing low cost, effective interventions. However, often these do not reach the most
vulnerable people where developing countries struggle to deliver essential health care with less
than USD 5 per capita per year. Optimising impact of existing interventions, services and
commodities requires both increased support to strengthen prevention and basic care efforts,
health systems and scaled up targeted support through innovative partnerships that reach
beyond the traditional health sector.
2. Increasing affordability of key pharmaceuticals through a comprehensive and
synergistic global approach.
Improving access to key pharmaceuticals can only be achieved through a comprehensive global
approach which addresses a global emergency.
Developing countries, in particular poor populations, have inadequate access to affordable
services and key pharmaceuticals. The reasons why are complex and beside the main ones
highlighted in area 1, they include the effects of international and national pricing policies,
tariffs and taxation and implementation of intellectual property rights agreements. Options to
further improve access and affordability include: exploration of the use of differential pricing
(tiered pricing), voluntary licensing agreements, parallel trading, technology transfer and
increase in local capacity for production, use of both generic and patented products and review
of tariff and taxation options at country level.
3. Increasing investment in research and development of global goods targeted at the
three major communicable diseases.
Research and development in the pharmaceutical industry is generally determined by the
demands of industrialised countries´ markets. Those diseases prevalent in developing countries
where markets are perceived to be small are neglected. Only 10 per cent of global health
research efforts target those diseases  which comprise 90 per cent of the global disease burden.
                                               
2 Key or essential pharmaceuticals are those medicines, including vaccines, which are essential to the
public health of a population.  Certain medicines for major diseases in developing countries may well
be 'essential or key' but may not appear on the WHO or country-specific essential drugs list (EDL)
6There is need to create global mechanisms and incentives to direct research and development
to diseases that disproportionately affect developing countries. Progress will require expansion
of the research portfolio, greater willingness to support risk investments, and a move from
serial to parallel testing of candidate products. Closer co-operation of the strong public
research tradition with the extensive capabilities of the European pharmaceutical industry could
bring significant benefits. A priority should be increased investment in the capacity of science
and technology institutions and personnel in developing countries.
The way forward
An accelerated Community response to the major communicable diseases should be seen as
part of and complementary to ongoing Community investments in health and poverty
reduction. For the response to be effective, coherent efforts of the Commission in conjunction
with the EC Member States, partner countries, international and civil society partners and
other stakeholders are required, as are greater innovation and more rapid action than
traditional development assistance allowed for so far.
The policy framework set out in this Communication is the Community's first response to the
recommendations of the G8 summit held in Okinawa in July 2000. The framework will be
broadly discussed during a high level Round Table with all interested parties, in particular
developing countries, EU Member States, European Parliament, international development
agencies, civil society, researchers and the pharmaceutical industry. The results of the Round
Table will provide valuable input to the Commission in formulating a programme for action.
71. INTRODUCTION
The complex interactions between the health of a population and poverty are now well
recognised. There is evidence that investments in health can make a major contribution to
poverty reduction and economic growth and that ill health is closely linked to poverty, poor
education and weak health systems3. In developing countries, communicable diseases,
particularly HIV/AIDS, malaria and tuberculosis, contribute disproportionately to high levels
of ill health and increasingly limit human development. World wide these three diseases
continue, despite existing efforts, to increase, and cause the deaths of more than five million
people each year with the greatest impact on morbidity and life expectancy in developing
countries.
These diseases can be partially controlled through improved living conditions and effective
public health and education systems. In principle each disease is preventable and/or readily
treatable using existing, effective and often low cost interventions including access to
information, health commodities (condoms, bednets) and services (treatment of sexually
transmitted and opportunistic infections, malaria and tuberculosis). However, too often
existing interventions fail to reach the most vulnerable.  There is also insufficient investment in
developing new and more effective interventions at all levels.
The lack of progress in reducing the burden of HIV/AIDS, malaria and tuberculosis through
support to strengthen health systems has brought these diseases to the centre of the
development debate and has led, in recent years, to the launch of a series of major initiatives.
These include: the International Partnership against AIDS in Africa (IPAA), the International
AIDS Vaccine Initiative (IAVI), the Global Alliance for Vaccines and Immunisation (GAVI),
Roll Back Malaria, the Malaria Medicines Initiative (MMV) and the Stop TB Initiative. A new
momentum has been generated and has been backed by increased financial commitments from
Governments4 and philanthropic groups5. New working approaches between the public and
private sectors are under formulation, such as the initiative of five pharmaceutical companies
and UNAIDS, to provide anti-retroviral drugs at more affordable prices.
This Communication proposes a policy framework to guide a coherent, comprehensive and
accelerated EC response to the three major communicable diseases as part of global efforts to
improve the health of the poorest as reflected in the recommendations of the G8 summit held in
Okinawa in July 2000.
This Communication briefly outlines the threats to global health and development, posed by
these diseases, and the challenges and opportunities in addressing them. It defines the role of
the Community in the context of new international initiatives. Finally, it identifies three core
                                               
3 World Bank 1993 World Development Report. The Commission on Macroeconomics and Health
(CMH January 2000) is producing a series of studies on how concrete health interventions can lead to
economic growth.
4 The G8 in Okinawa committed to accelerated action against the major communicable diseases.
Specific pledges were made by Japan (USD three billion) and The United Kingdom (USD 160
million). The International Development Association (IDA) announced a total credit of USD 1 billion
to combat AIDS, Malaria and TB.
5 In 2000 only, the Bill and Melinda Gates Foundation has provided grants of USD 90 million for
malaria, USD 90 million for HIV/AIDS actions and more than USD 100 million for TB related
actions.
8areas for increased Community action and recognises that effective action will require
integrated efforts of the Commission in collaboration with partner countries, international
partners and Member States.
This Communication will be broadly discussed during a high level Round Table with all
interested parties, in particular developing countries, EU Member States, European Parliament,
international development agencies, civil society, researchers and the pharmaceutical industry.
The Commission will report on the results of the Round Table, and present its proposals for
intervention in a forthcoming programme for action.
2. CHALLENGES AND OPPORTUNITIES TO REDUCE THE BURDEN OF
MAJOR COMMUNICABLE DISEASES IN DEVELOPING COUNTRIES
2.1. Health systems are under pressure
Health systems6 in the poorest countries are under enormous pressure and commonly lack
resources to provide even a basic level of care. Health services are under-funded, short staffed,
lack adequate essential equipment and supplies and often have limited institutional and
management capacity. Typical annual per capita public health expenditure in sub-Saharan
Africa is less than USD 5 or 2.5% of GNP. 7  This compares with a World Bank 1993 estimate
of USD 12 per capita per year, or 3.4% of GNP, needed to deliver a basic selective package of
care.
More recent work by WHO (World Health Report 2000) suggests that total annual health
investment of less than USD 60 per capita is likely to be ineffective. Such low levels of
investment are able only to sustain minimally functional services, even where efforts to reform
and restructure health systems are successful. While Government health care services are
usually intended to reach the poor they often disproportionately benefit the better off. The
increasing impact of HIV/AIDS, malaria and tuberculosis has further exacerbated the gap
between need and available resources. Recent financing reforms attempt to correct this bias.
Securing adequate resources to produce better health outcomes remains a struggle in most
developing countries and progress towards the development of more efficient and equitable
health systems is a slow process. Significant increases in the health share of national budgets
are unlikely to materialise. Several of the poorest countries report capital expenditure of 40-
50% of their total public health budget. Most of what is left goes to staff with only a very small
portion remaining for maintenance and consumables. Payment for services funded through
general government revenue prepayment schemes and social health insurance remains the
                                               
6 Health systems defined broadly (WHO World Health Report 2000), include all of the non-personal,
population-based or public health interventions such as healthy life styles, insecticide spraying against
vector borne diseases, anti-tobacco campaigns, the protection of food and water as well as personal
services.
7 Statistical data within this Communication are based on most recent figures provided by WHO,
UNAIDS and DAC unless otherwise indicated.
9preferred and most equitable approach to fair8 financing of basic services and commodities for
public health. This approach has led to the greatest improvements in access to care9.
Where publicly funded care is not sufficiently available to cover basic healthcare costs, ill
health exposes families to large unplanned expenditures. Such expenses can account for up to
half of total monthly income and can push families into poverty. Much of this expenditure is
particularly for services and pharmaceuticals.
2.2. Major communicable diseases are a global challenge
Communicable diseases are responsible for 60 per cent of the total burden of disease in
developing countries. HIV/AIDS, malaria and tuberculosis comprise a major proportion of this
burden and together they cause the deaths of more than five million people annually. Most of
those affected live in developing countries and women are especially vulnerable.  There is
evidence that the impact of these diseases is increasing due to continuing and worsening levels
of poverty, the effect of population growth, the increase in man-made and natural disasters
resulting in displacement of populations, the failure of health systems, the emergence of
resistance to medicines, increased injecting drug use, climatic changes and deteriorating
sanitation. The global emergency caused by HIV/AIDS, malaria and tuberculosis is further
detailed in Annex 1.
In addition, communicable diseases do not respect national borders and the failure of control
measures in one country can put neighbours and global health at risk. Only 10% of the
predicted illness and death due to HIV/AIDS have occurred to date and the full impact of this
epidemic on people, communities and economies is still to come. Despite 15 years of concerted
effort, the epidemic is out of control in many developing countries.
Malaria is re-emerging in areas where it was previously under control or eradicated. The most
widely used and effective vector control tools, such as DDT, pose wider environmental threats
to human and animal health. While recognising the need to control the use of commonly used
persistent organic pollutants such as DDT, there is inadequate investment into research to
develop and test alternatives. The cheapest and most used treatment for malaria is rapidly
losing its effectiveness.
It has been possible to diagnose tuberculosis for more than a century, and to effectively treat
the disease for at least 50 years, yet it remains a leading killer.  A course of treatment for one
patient costs as little as USD 11. With the present approach only half of the estimated total
number of cases are detected. Less than half of those diagnosed complete treatment.
Furthermore, the emergence of resistant strains of tuberculosis, linked to HIV/AIDS, poor
compliance with treatment prescriptions, or irrational prescriptions, threatens to make existing
drugs ineffective world-wide. TB has increased four-fold in many developing countries and has
re-emerged after steady decline in parts of Eastern Europe.
                                               
8 Fair financing in health systems means paying according to ability to pay rather than to the risk of
illness. This implies that poor people should pay less for the same services.
9 The increase in social and private health insurance coverage and expanded drug benefits is a
promising trend in countries as diverse as Argentina, the People’s Republic of China, Egypt, India, the
Islamic Republic of Iran, Georgia, South Africa, Thailand and Vietnam. Some programmes have
special arrangements for rural and low-income populations. Drugs represent 25% to 70% of total costs
for these schemes.
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2.3. The need for an effective global response
Countries where people enjoy higher levels of health experience faster economic growth10.
There is evidence that improvement in health accounts for a significant proportion of the rapid
economic growth of much of the world in the 20th century. Effective education and public
health systems are essential prerequisites for poverty reduction and development.
Research demonstrates that targeted investments in the control of communicable diseases can
improve the health of the poorest.  WHO calculates that doubling the projected rate of decline
of common communicable diseases would disproportionately benefit the poor, leading to an
increase of life expectancy of 4.1 years for the poor against 0.4 years for the rich (World
Health Report 2000). The greatest potential impact on reducing the burden of these diseases
could be achieved by a complementary and synergistic approach, which increases investment
across three main areas.
First, much of the disease burden arising from the three communicable diseases could be
reduced through more effective access to, use, and impact of existing interventions. These
remain underused and often do not reach the most needy; much more could be achieved with
existing technologies and interventions. This requires intensified support to strengthen health
systems to ensure improved access to prevention and treatment for the poorest and most
vulnerable people. However, the global and national emergency created by these three diseases
will not wait for the improvement of health systems; there is also a need for simultaneous
actions beyond the traditional health sector. These must use innovative approaches in health as
well as in other "enabling" sectors, such as education or transport, through increased
partnerships and faster delivery mechanisms. WHO and UNAIDS have estimated the additional
resources needed to provide specific outcomes through accelerated and more effective delivery
of existing interventions including information, health commodities and services over the next
five years (Table 1).
Table 1 Proven cost-effective interventions for malaria and TB with potential for wider use through new
mechanisms
Intervention Resources USD Target Group 2005 Outcome
Impregnated bednets 1.5 billion All children in Africa
protected from malaria
600,000 child deaths prevented
per year
Anti-malarial drugs 4 billion 100 million children
reached in malaria
endemic areas by 2005
25 % reduction in mortality
due to malaria
Anti-tuberculosis drugs 1 billion 70 per cent of new cases of
TB provided with effective
treatment by 2005
50 per cent reduction in deaths
caused by TB
Source: WHO briefing
                                               
10 This was first revealed in the World Bank 1993 World Development Report.
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Cost estimates for HIV/AIDS prevention and care activities in sub-Saharan Africa are
estimated at USD 1.5 billion yearly for prevention (including youth focused and sex worker
interventions, public sector condom provision, condom social marketing, STI services,
voluntary counselling and testing (VCT), blood transfusion services, mother to child
transmission (MTCT), media, workplace interventions, start-up capacity development and
surveillance, monitoring and evaluation) and USD 1.5 billion yearly for care programmes
(including essential HIV care but not Highly Active Anti Retroviral Treatment (HAART)11.
Most interventions are already being delivered through actions both inside and outside the
formal health sector. Many are being, or could be, provided as over the counter products and
services, through social marketing, through non-health workers or through franchising
mechanisms.
Second, there is considerable potential to improve affordability of key pharmaceuticals12. for
the poorest through global approaches and instruments. One-third of the world’s population,
and in the poorest parts of Africa and Asia over half of the population, do not have regular
access to the most vital and essential pharmaceuticals. In developing countries, up to 90% of
medicines are paid for "out-of-pocket" directly from household revenues. This expenditure can
represent 50% of household spending and can contribute to impoverishment.
Affordability of pharmaceuticals is a complex issue but price of commodities, and the inability
of most people to pay, is seen as a major obstacle to improving access in developing countries.
Developing countries often lack the price control mechanisms which exist in industrialised
countries, and the larger part of the ultimate consumer price can consist of import duties,
taxes, distribution costs and dispensing fees.
Greater attention to affordability issues has led to a series of proposals for international action
in the areas of implementation of intellectual property agreements, promotion of generic drug
policies, pricing mechanisms, tariffs, bulk purchasing, technology transfer and increasing
production capacity in developing countries.
Intellectual property rights, including patents, are addressed through the Agreement on Trade
Related Aspects of Intellectual Property Rights (TRIPS13) and bilateral agreements. Patent14
protection aims at giving incentives for the development of new products and at ensuring
publication and disclosure of new innovations to the benefit of the public. To recover costs of
product research and development and to generate the necessary resources to invest in new
                                               
11 Estimates based on cost of HAART of USD 1400 per person per year would result in resource needs
for sub-Saharan Africa of at least USD 1 billion per year.
12 Key or essential pharmaceuticals are those medicines, including vaccines, which are essential to the
public health of a population.  Certain medicines for major diseases in developing countries may well
be 'essential or key' but may not appear on the WHO or country-specific essential drugs list (EDL)
13 Agreement on Trade Related Aspects of Intellectual Property Rights –adopted after the Uruguay
Round in 1994 to establish the minimum standards of patent protection that must be followed by all
member countries of the World Trade Organisation (WTO). Application of the agreement is subject to
the transitional arrangements contained in articles 65 and 66 of TRIPS.
14 A patent is a title granted by the public authorities conferring a temporary monopoly for the
exploitation of an invention upon the person who reveals it, furnishes a sufficiently clear and full
description of it, and claims this monopoly. The product should be new, involve an inventive step and
be industrially applicable. Generally the invention may relate either to a product or a process including
pharmaceuticals.
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products, the inventors get an exclusive period of time to commercialise their new products.
However, some representatives of civil society and some developing countries have expressed
concerns that high prices are not always related to recovering investment costs and may delay
the competitive forces of the market to reduce prices.
The Commission has initiated a dialogue with different stakeholders in order to assess the
implementation of intellectual property rights.  It is recognised that TRIPS provides a number
of safeguards including specific exceptions to patent rights, notably compulsory licensing15.
Together with its partners from developing countries, the Commission will further explore the
existing safeguards. Experience with vaccines and contraceptives demonstrates that significant
price differentials can be achieved between prices in developed and developing countries. Some
pharmaceutical companies have indicated a willingness to have similar price differentials for
other pharmaceuticals, including newer patented products. This has led to a recent
announcement of a significant price decrease for some anti-retroviral drugs. Although the
percentage of people with HIV who will be able to benefit from lower prices will initially be
low, it is expected that incremental progress can be made. Such initiatives should be carefully
monitored to ensure that scarce public finances that target prevention and services for the
poorest and the many are not diverted to non-curative treatment for the few.
Third, there is need for more effective and increased global investment in the development of
new products, particularly vaccines, vector control products and drugs targeted at controlling
the three major communicable diseases. Only 10% of global health research funds are presently
targeted at 90% of the global disease burden. Developing countries represent less than 15% of
the total value of the global pharmaceutical and commodity market; this results in extremely
limited investment into new tools against those diseases with the greatest public health impact.
There are particularly stark deficiencies in the development of new technologies against
HIV/AIDS, malaria and tuberculosis which each kill more than one million people each year.
New vaccines, diagnostics, pharmaceuticals and insecticides will all be required for maximum
impact. The cost of developing these technologies is very high, ranging from USD 100 million
for a new treatment to USD 500 million for a successful vaccine. The complexity of the
science, the efficacy of potential new products, the safety profile, the high development costs
and the uncertain outcome of research and development all represent significant obstacles to
investment. Yet the challenge and potential benefits to global health and development are
massive and require increased and more effective public and private sector investment.
Populations in developing countries and the global community will be the beneficiaries of
increased knowledge and new products.
2.4. New international partnerships
Many countries are in the midst of redefining their health policies and systems. In many highly
aid- dependent countries, governments and donors are moving towards a sector wide
approach, setting a broad policy framework and establishing longer-term partnerships. This
process takes time16. The scale of the communicable disease problem requires that ongoing
                                               
15 TRIPS article 31. Compulsory licensing is the granting of a license without the consent of the patent
holder on various grounds of general interest.
16 Walt and Smithson report: Before Ghana’s single sector programme was endorsed by donors, the
country had gone through 10 years of institution development, 4 years of policy and strategy work, 3
years of strengthening management, 2 years of negotiations, planning and design and 1 year of
slippage and delays.
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efforts to make health systems more effective and responsive need to be complemented by
accelerated action. This has led to a series of targeted initiatives over recent years in which the
European Union has largely been involved.
The UN Security Council, the World Bank Development Committee, and the G8 have
recognised the threat to development and security posed by HIV/AIDS, and have questioned
the adequacy of measures to confront the pandemic. Promising new initiatives include the
International Partnership against AIDS in Africa supported by a coalition of UN agencies,
donor governments, private and community sectors and African governments. The EC's
initiatives to increase investments in developing new products, including AIDS and malaria
vaccines, a microbicide and new medicines, are also encouraging. The initiative of five
pharmaceutical companies and UNAIDS to provide anti-retroviral medicines for HIV/AIDS at
more affordable prices is also a promising development. Donor funding for HIV/AIDS,
estimated at USD 300 million in 1998 falls far short of need.  Yet there are now positive signs
of significant increases from Governments and the private sector. The EC is an active
participant in these interventions.
A series of high level meetings in recent years have provided renewed political impetus to the
fight against malaria. The G8 (Birmingham 1998, Cologne 1999, Okinawa 2000), the EU-US
summit (Queluz 2000), the EU-Africa summit (Cairo 2000), the African Heads of State
meeting in Abuja in March 2000 and the social summit in Geneva (June 2000) have all led to
calls for accelerated action.
The WHO Roll Back Malaria initiative is now gaining momentum. The European Malaria
Vaccine Initiative (EMVI) combines efforts of Commission, EU Member States and industry in
malaria vaccine development17. The EU supported African Malaria Vaccine Testing Network
(AMVTN), which generates human and institutional capacity in Africa, is instrumental in
accelerated testing and deployment of malaria vaccines. The EC is also supporting large R&D
project clusters on HIV, malaria and tuberculosis vaccines involving extensive industrial
partnerships. Other innovative partnerships, such as the Medicines for Malaria Venture
(MMV), which bring together public and private sectors, offer a promising route to the
development of new drugs. The EC is involved in negotiating the control of the use of
persistent organic pollutants (PoP) such as DDT18.
The Stop TB Initiative, launched by WHO in 1998 and the Amsterdam TB conference (2000)
have defined an agenda for action targeted at the most affected countries. Donors have
indicated plans for scaled up and improved support to confront the disease.
There are many opportunities for the international community to explore the use of innovative
financing partnerships, including with the private sector, and financing mechanisms that
leverage additional investment. Several philanthropic agencies have provided substantial
support to the fight against communicable diseases. Public-private partnerships are increasing,
and the development banks are exploring possible new facilities to support work on
communicable disease control.
                                               
17 The initiative already produced tangible results: two European developed malaria vaccines are
entering clinical trial this year. EMVI is participating in the Global Alliance for Vaccines and
Immunisation (GAVI).
18 The EC accepts the continued, but time-limited production of DDT for vector control for public health
purposes as supported by the African Consultation on reduction of reliance on DDT held in Harare in
February 2000.
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An effective future global response will require closer integration and synergy between these
multiple initiatives with effective dissemination and incorporation of lessons learned.
3. EUROPEAN COMMUNITY´S SPECIFIC ROLE IN ADDRESSING MAJOR
COMMUNICABLE DISEASES
3.1. The EC's current policies and ongoing activities
The EU (European Commission and Member States) together provides 55% of all
development assistance and 65% of world assistance for Health, AIDS and Population in
developing countries. In 1998 the European Community committed Euro 8.6 billion of
development aid.
The goal of the new EC Development Policy (COM (2000) 212) is poverty reduction. One of
the priority areas for EC development aid is the support to macroeconomic policies in
developing countries with an explicit link with poverty reduction strategies, in particular sector
programmes in social areas (health, education) 19. The EC Health, AIDS and Population (HAP)
policy and programmes are being re-formulated in relation to this goal, through a variety of
complementary instruments. In 1998, Euro 700 million was allocated to the Health AIDS and
Population portfolio20 (see Annex 2).
The EC development policy is evolving in the following ways: from project to sector support,
from infrastructure to systems strengthening and institutional development and towards greater
integration of cross-sectoral themes. There has also been a shift in policy focus towards
targeting poorer communities in developing countries. The EC's HIV/AIDS policy and
programmes have mainly supported poverty reduction strategies through sustained cross-
sectoral prevention efforts (53% of the activities financed 1987 - 1997 - see Annex 2) and
primary health care (42% of the activities financed 1993 - 1997). Investment in knowledge
generation has been at the core of research programmes, which increasingly target the priority
issues of developing countries.
EC health support has strengthened systems, health services and pharmaceutical access with
extensive support to improve capacity for procurement, distribution and rational management
of pharmaceuticals as part of wider efforts to reform health systems. EC/WHO support has
facilitated 21 African countries to work collaboratively on issues related to pharmaceutical
policy. Specific contributions have been made over the past 10 years in 30 developing
countries to develop sustainable and fair financing mechanisms and to the development of more
efficient procurement and distribution systems, regulatory capacities and quality control for key
pharmaceuticals with specific emphasis on contraceptives, vaccines and generic medicines.
The EC has supported capacity building to enable regional action against emerging and re-
emerging communicable disease threats. This has included enhanced surveillance and control
efforts, in co-operation with WHO.  Ensuring effective risk management of communicable
disease outbreaks is a key feature of EC humanitarian assistance programmes. The EC also
supports WHO’s action plan for the reduction of the reliance on products such as DDT.
                                               
19 COM (2000) 212, p. 25.
20 Figures include estimates from structural adjustment funds.
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The EC HIV/AIDS programmes have made a major contribution to defining safe blood policy
and practice, in particular in influencing the shift from a reliance on paid donors to a volunteer
base. In Uganda volunteers now provide 60% of the national blood supply. The EC co-funded
the influential Mwanza study (Tanzania), which identified that effective treatment of sexually
transmitted diseases could reduce HIV transmission rates by 40% or more (see Annex 3). The
findings of this study have influenced global HIV/AIDS control efforts. EC support to youth
targeted education programmes in South Africa have led to significant falls in HIV
transmission rates in this age group. Despite the successes, the scale and impact of HIV/AIDS
interventions have been insufficient.
While the EC has not provided substantial targeted support to malaria and tuberculosis
initiatives it has made an impact through a major contribution to health systems development in
many countries. The EC supported ARIVAS programme has worked with ten countries in
West Africa to incorporate finance of priority public health vaccines including tuberculosis
vaccine into national budgets. The EC is involved in new international partnerships specifically
related to malaria as detailed in 2.4.
The EC has played an active role in debates on improving access to and effective use of
medicines. Assistance is provided to developing countries to ensure that national legislation
and international agreements on trade are respected.  The Commission has started to address
questions linked to access to pharmaceuticals, such as pricing mechanisms, investment in new
products, and the impact of international property rights.  It is encouraging the participation of
a wide range of stakeholders to achieve well-balanced solutions.  These include research-based
and generic pharmaceutical industries, NGOs, national governments and international
organisations.
Europe has a long-standing tradition of excellence in vector control and pharmaceutical and
medical research. European industries have considerable Research and Development (R&D)
capital and skills. More than 60% of the vaccines currently used in developing countries are
produced in Europe and several EU companies are among the largest producers of anti-
infective drugs.
The Commission supports a long established R&D portfolio targeted at communicable diseases
with more than Euro 50 million committed for new research under the first rounds of
applications to the new 5th Framework Programme. More than 40 malaria projects were funded
under the last framework programme. The EC has supported important new public-private co-
operation projects, involving WHO, which seek to stimulate research and development of new
medicines and vaccines of particular importance to the health of people in developing
countries. Internationally very relevant activities were supported. Most of the possible malaria
vaccine candidates have been initially characterised in EC projects. An EC funded trial in The
Gambia in collaboration with US researchers and industry on a vaccine candidate is the first to
show protection in a majority of vaccinees for more than a month. At least one new
tuberculosis vaccine candidate is ready for preliminary testing and several new prototypes will
be forthcoming very soon for HIV, including for the types most prevalent in developing
countries. Research on a totally new class of anti-malarial drugs is also supported. EC funded
North-South collaborative research was first to show the epidemiological links between HIV
and tuberculosis in Zambia and between HIV and other STDs in Africa. Results of very
detailed investigations on transmission give new explanations on how fast people are re-
infected after initial cure of tuberculosis. In addition, the EC provided substantial funding for
16
environmentally friendly vector control research in order to develop new technologies and
reduce the use of insecticides, and this could also be applied to the malaria vector.
Disease prevention and promotion of health will continue to be the main focus of all health and
development efforts. The EC intends to build on past successes and increase support for
proven and effective prevention interventions and to improve primary health services. Support
to health reform is valid and will be continued in the longer term. However, the scale of the
problem created by the continued spread of the three major diseases warrants additional
accelerated and more targeted complementary responses.
3.2. The EC’s comparative advantage in recent development strategies
Since mid 1990s those involved in development assistance have attempted to work through
more effective national and international co-ordination mechanisms, through innovative
partnerships and with greater focus on developing countries´ capacity building. More attention
is being directed to ensure that public and private investments are made in the social and health
environments of the poorest countries and populations, that these investments benefit the
poorest and that they target the highest priorities. A set of ambitious, internationally shared
development targets has been endorsed, setting the development agenda for the next 15 years.
The EC has re-oriented its own strategies taking into account its comparative advantages and
financing instruments.
With a strong poverty reduction mandate, the EC has a particular and important role to play in
health, including to confront the problems of communicable diseases affecting the poor more
effectively and rapidly. The range of Commission competencies and instruments across the
vital areas of humanitarian assistance, development, environment, trade and enterprise,
research and international health is unique and provides potential for greater synergy between
many policy areas. In addition, the EC is active in all developing countries and provides
substantial grant aid assistance. The developing country partners (in particular the Least
Developed Countries) have a greater role in all aspects of the aid management cycle than with
other most donor aid.
The following paragraphs present a policy framework. Specific proposals for action will be
developed following wide consultation and will detail the legal basis and financial instruments
proposed. The legal bases for further contributions include development co-operation (articles
177 et seq of the EC Treaty) including co-operation with international organisations (article
181), public health (article 152) and research policy (article 163 et seq). Special instruments
applicable to this field include the Council regulation 550/97 on HIV/AIDS in developing
countries, which is under review.
4. THREE CORE AREAS FOR INCREASED AND ACCELERATED ACTION
The Commission shall continue and accelerate its support for existing interventions in health
but also reinforce promising approaches. Three broad areas for accelerated action are identified
and presented below, building on the comparative advantage, policies and instruments of the
EC.
These areas are to complement, and not replace, existing actions. They are proposed as
mutually interdependent reinforcing actions. No action in one particular area can be efficient
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without significant and sustained support in the other two areas. The mix of the areas of action
offers the potential to deliver positive outcomes over the years.
This strategy mix consists of actions to:
· Optimise impact of existing interventions.
· Increase the affordability of key pharmaceuticals through a comprehensive global approach.
· Increase investment in research and development of new medicines and vaccines targeted at
the three diseases.
These three areas have been highlighted because of their direct relevance to the fight against
communicable diseases. However the Commission does not regard these areas as the only ones
important to successful communicable diseases control. Ongoing EC interventions in areas
such as good governance, conflict prevention and resolution, corruption, transport,
infrastructure, education, gender equality, and the fight against the production, trafficking and
use of illegal drugs, are all being pursued for their wider beneficial and development impact but
will also have a positive effect on communicable disease control. Continued EC action in these
areas and above all a continued commitment by partner governments to take action, are
essential if the major communicable diseases are to be controlled.
4.1. Reaching optimal impact of existing interventions in EC development co-
operation.
Public health systems have had varied success in providing effective services to the poor.
Government health systems, however, will continue to serve as the largest single provider of
preventive measures and curative services for the three diseases. The EC will improve its
efforts to strengthen health systems, provide for key commodities and pharmaceuticals,
support national budgets, scale up effective approaches and improve donor co-ordination.
Delivering a major increase in access and utilisation of effective interventions will involve
working through multiple complementary channels. These would include NGOs/CBOs, the
for-profit private sector, and traditional providers.
There are under-exploited opportunities to scale up approaches, which have proven
effectiveness and to develop innovative mechanisms and partnerships to reach the poorest.
Useful experience has been gained in franchising, social marketing, use of voucher schemes,
over-the-counter sales of non-prescription items, public-private collaboration, regulation and
contracting. Many of these small-scale pilots could be scaled up. Others such as social
marketing may need to be further refined to reach those who are presently too poor to benefit.
Important elements will be the provision of information on which consumers can make
informed decisions and attention to regulatory and legal frameworks to strengthen consumer
rights.
Adequate and ring-fenced public finance (external and domestic) for priority preventive and
curative interventions is essential if poor people are to have access to care. However, a range
of financing mechanisms needs to be considered. The appropriate approach will depend on
country context, and will need to be pluralistic.
The following policy orientations will guide future action:
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· Focus on preventive activities should remain the EC´s main long-term response in
addressing the three major communicable diseases.
· Encourage developing countries to establish coherent and integrated health policies
designed at targeting major communicable diseases. This includes ensuring that an
adequate balance between prevention and care is maintained in the delivery of Community
assistance.
· Establish and strengthen innovative partnerships and national mechanisms that involve
governments, but also reach beyond the government health system. Examples could
include partnerships with civil society organisations, support for organisations experienced
in the social marketing of health commodities, partnerships with private sector distribution
networks and qualified private providers. Such an approach will require high quality market
research on behaviour and attitudes that might affect the use of commodities or
interventions.
· Develop sustainable mechanisms for progressive, prepaid financing for effective
prevention and care interventions, which would exempt the poor and provide subsidies
for the near-poor, thus opening up markets for low cost commodities and health
interventions.
· Support the growth of strategic purchasing, including the use of contractual or
franchising arrangements, by public fundholding bodies in the health sector for qualified
providers of all types (public, private, not-for-profit). Ensure incentive systems, which
favour rational selection and safe, economical use of technologies, which promote and
improve health, by providers of all types.
· Support for improved delivery mechanisms and quality insurance for commodities and
interventions that are effective, such as condoms, bednets, prevention of mother to child
transmission, voluntary counselling, HIV testing and care for people with HIV/AIDS,
sexually transmitted infections (STI), tuberculosis and malaria.
· Support will be focussed on those countries which demonstrate a commitment to
equitable access to essential services and which demonstrate positive outcomes for the
poorest segments of the population. This includes the development of fair financing
strategies21 and responsive, accountable health systems.
The EC and the international community are exploring innovative financing partnerships that
may also induce the private sector to mobilise additional investment. This global partnership
will co-operate with specialised UN agencies, such as WHO and UNAIDS, to back country-
based initiatives with demonstrated ability to increase access to, and make effective use of, key
commodities and interventions, disseminate lessons learned, inspire others and catalyse more
widespread and effective actions.
                                               
21 For the definition of fair financing, see The World Health Report 2000, p. 35-39.
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4.2. Increasing affordability of key pharmaceuticals through a comprehensive
approach
Almost 90% of the products on WHO’s “essential drug list” are not patented and therefore are
subject to generic competitive tendering and local production. In principle they are available at
lower prices from generic or original producers. Yet still many of these products do not reach
people in developing countries for reasons highlighted in 4.1.
Several key products to prevent, diagnose and treat HIV/AIDS, malaria and tuberculosis are
largely produced in industrialised countries, under patent, are still too expensive for the poor.
Consumer prices can vary widely within, as well as amongst countries, because of differences
in market demand, intellectual property rules, purchasing capacity, tariff levels, differences in
local incomes, the lack of a sustainable market, price setting and the degree of competition
among generic and the R&D-based pharmaceutical industry producers. The Brazilian
government has recently started to produce 7 of the 12 drugs used to assist people with
HIV/AIDS. The prices of those drugs have fallen 70% on average, while prices of medicines
bought in international laboratories, have fallen less than 10% in the same period 22.
Affordability of key pharmaceuticals can only be increased and accelerated through a
comprehensive synergistic approach. The EC recognises that the price of essential drugs and
key pharmaceuticals needed to prevent or to treat the three major communicable diseases is
one of the major obstacles, but not the only barrier, to improving access to health and health
care for the poor in developing countries.
The following policy orientations will guide future action:
· The EC will increase its present support to countries to strengthen national
pharmaceutical policies and practice including procurement, tendering, distribution,
quality assurance and technical capacities to improve the availability of essential and key
medicines at country level.
· The EC recognises the need for the careful review of pricing of key pharmaceuticals for
the three major communicable diseases and the impact of import tariffs and taxes, taking
into account effects on the tax base and on public expenditure. Greater transparency
regarding the breakdown of consumer prices on key pharmaceuticals will also be pursued.
· The EC also advocates that industry use tiered pricing to allow manufacturers to offer the
lowest possible prices to the poorest countries without threatening profits in developed
countries.23 This should build on a volume/price trade off. Where lower income countries
benefit from (low) preferential prices, effective measures need to be in place to prevent
parallel exporting to (higher price) developed countries. The EC will further examine the
impact of parallel trading,24 taking into account that the general principles of community
law allow patent holders to oppose parallel trade from outside the EEA.
                                               
22 Government of Brazil: Report to International AIDS conference, Durban, July 2000.
23 Tiered pricing has long been practised in relation to childhood vaccines.
24 Parallel trading involves cross-border trade in a product without the manufacturer’s permission – i.e.
helps lower drug prices by enabling buyers to shop around for the cheapest drug sources, whether they
are patent holders or not. For parallel trading from outside of the EU and exhaustion of rights (for
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· Other possibilities could be through engagement in voluntary licensing agreements to
facilitate local production of key pharmaceuticals and to ensure that developing countries
benefit from technology transfer.
· The generic and R&D based pharmaceutical industry are invited to develop and co-operate
with the local pharmaceutical industry and research institutions in developing countries,
provided effective competition is ensured on domestic markets. This would contribute to
increasing capacity for local production of generic drugs and enable fair competition
from generic drug manufacturers. The EC will also work with the governments from
developing countries to facilitate local production.
· The EC acknowledges that developing countries can use, when appropriate, the flexibility
within the TRIPS Agreement to provide compulsory licensing25 (article 31 of TRIPS) to
address public health concerns and emergency crises. In doing so the EC also takes
into account the need to respect the property rights of the patent holders. Together
with its partners from developing countries, the EC will explore the flexibility provided by
the TRIPS Agreement to address public health concerns and emergency crises.
The EC will provide technical assistance for countries to implement the TRIPS Agreement.
The EC and their Member States should co-ordinate and enhance their technical assistance
with developing countries aiming at their full compliance with the TRIPS Agreement.
4.3. Investment in research and development of global goods targeted at the three
diseases.
Actions identified in the previous sections seek to address access and affordability issues that
can make an impact on communicable diseases in the short to medium term. They are to
increase the attractiveness of the market and protect the environment and intellectual property
rights. However, more attractive markets alone will not provide adequate incentives for new
investment. This will also require measures targeted at the various stages of the research and
development process. They are to overcome obstacles from the past: insufficient co-ordination
between players, insufficient identification of the means necessary and lack of institutional
capacity building in the countries hardest hit by the epidemic.
The EC proposes to address the multiple barriers for further investment in research and
development through three complementary strategies consisting of larger scale and more
effective public investment, development of an incentive package for private investment and
participation in a global partnership.
Larger scale and more effective public investment. The Community has made a significant
past contribution to the research agenda through the Biomed Specific Programme of the 4th
Framework Programme and through key actions on ‘control of infectious diseases’, and
‘quality of life’, as well within the INCO programme in the 4th and 5th Framework Programme
(see Annex 4). Recent initiatives have increasingly focused support on confronting
communicable diseases in developing countries. The EC proposes to scale up the different
                                                                                                                                                  
trademarks), see the following ECJ cases: Silhouette International (Case C-355/96) and Sebago (Case
C-173/98) .
25 The granting of a license without the consent of the patent holder on various grounds of general
interest.
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components of the R&D process and to further increase coherence between Community and
other R&D activities. The goal is to rapidly enlarge the R&D pipeline, to accept a greater
degree of investment risk and to accelerate the process through a move from serial to parallel
testing of candidate products. Reinforced co-ordination with Member States on common
strategic R&D will be the key to this acceleration.
Under the new European Research Area policy framework (ERA), the EC proposes to
increase support for capacity building of research institutions and personnel in developing
countries. It seeks to ensure that researchers from developing countries are more involved in
early priority setting within the EC R&D process and that countries which host clinical trials
see their communities and scientists both participating adequately in the exercise and benefiting
from the results. Most rigorous ethical standards need to be established and observed. A
specific Communication on research against major communicable diseases is being prepared.
Development of an incentive package for private investment.  Accompanying measures to
build capacity and further develop innovative public-private partnerships are needed. Increased
private investment in R&D will be encouraged through appropriate incentives. The EC intends
to explore options to improve the expectations of companies that a future market will enable
return of their investment costs for R&D.
Possible incentives which require further study are two-fold: low cost loans and other
incentives for venture capital especially important for small biotechnology firms doing most of
the early research and development of vaccines and drugs; and purchase funds. The
international debate on possible operationalisation of such funds is ongoing26. Producers of
newly licensed vaccines could be granted rights for limited patent extension on unexpired drug
or biological patents for which the owner is the holder of the exclusive license. Innovative
public-private licensing agreements already tested for HIV/AIDS vaccine development could
also be extended more widely.
There is great scope to improve availability of information at all levels. Developing country
partners need easier access to complex but publicly available patent information.
Pharmaceutical companies need improved information on potential markets for products; this
could be provided through market exercises such as that performed by the EC for
microbicides, condoms and an HIV/AIDS vaccine. Early sharing of intellectual property rights
related to extensive research partnerships will be encouraged.
Participation in a global partnership, to make the health research agenda more responsive
to the global needs in the next decade. The EC together with WHO, the World Bank and other
main partners in health and development will come together to influence a more responsive
health research agenda for the next decade. The effort will seek to reorient health research,
both public and private, from the present ratio of 10% investment in 90% of the global burden
of disease towards a more favourable 20/80 ratio. This shift appears to be a realistic goal and
further monitoring tools need to be developed.
                                               
26 Here the distinction is often made between ‘push’ and ‘pull’ mechanisms. Examples of push
mechanisms are public investment in research and tax breaks linked to investment for research by
private companies. Examples of pull mechanisms are purchase funds and transfer of patents. It is
argued that without sufficiently strong pull mechanisms, the new drugs and vaccines will not be
developed and be put into use, even if the ‘push’ is successful in developing candidate vaccines.
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5. CONCLUSIONS AND RECOMMENDATIONS
A new international effort to reduce the impact of the key diseases that keep the poor in ill
health and poverty and hold back development is long overdue. The international environment
is supportive and the new and evolving partnership with WHO and closer collaboration
between stakeholders, including the World Bank and UNAIDS, offer a new opportunity that
should be built upon. The Community proposes to make a substantive contribution to the
international effort using the various instruments at its disposal.
The policy framework set out in this Communication is the Community's first response to the
recommendations of the G8 summit held in Okinawa in July 2000. The Commission will
elaborate a programme for action along the lines of chapter 4 above. In formulating the
programme for action the Commission will benefit from additional consultations with
important stakeholders, including developing countries, Member States, Members of European
Parliament, international development agencies, civil society, researchers and the private
sector, at a high level Round Table to be held in Brussels on 28 September 2000.
The Council and the European Parliament are invited to work with the Commission to take
forward the ideas in this Communication.
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Annex 1
Global emergency cause by HIV/AIDS, malaria and tuberculosis
HIV/AIDS
· HIV/AIDS kills over 2 million people in Africa alone each year – more than 10
times the number that perish in wars and armed conflict during the same period.
· In 1999, 33.6 million people world-wide were estimated to be living with
HIV/AIDS with over 16 million people deaths since the start of the epidemic.
· 95% of infections are in developing countries with two-thirds in sub-Saharan
Africa where HIV prevalence has reached 30% of the adult population in seven
countries.
· In 1999 an additional 5.6 million people were infected including 570,000 children
born to HIV positive mothers.
· Women are particularly vulnerable to HIV infection due to both social and
biological factors.
· 11.2 million children are orphaned due to AIDS.
· HIV/AIDS spreads fastest in conditions of poverty, social instability and
powerlessness. Such conditions are at their most extreme during emergencies.
· HIV/AIDS is reversing important developmental gains; in parts of Southern Africa,
infant mortality has increased by 25% and life expectancy has fallen from 64 to 47
years over a period of just three years.
· HIV/AIDS affects adults in their economically productive years; per capita income
may be reduced by as much as 0.5% per year where more than 8% of adults are
infected.
· Prevention by reducing vulnerability and curbing transmission of the virus remains
the most effective strategy to control the spread of the epidemic.
· The availability of care and medicines for HIV/AIDS has significantly reduced
disease and mortality caused by HIV/AIDS in industrialised countries; the vast
majority in developing countries are deprived of all drugs including those for
treatment of common opportunistic infections.
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        Malaria
· Malaria kills at least 1 million people each year and infects 500 million people.
· 90% of cases occur in Africa while 40 percent of the world's population is at risk.
· The major impact is on women and children - 700,000 children will die from
malaria this year - one death every 30 seconds. Women are four times as likely to
suffer malaria attacks during pregnancy.
· Malaria control and treatment costs African countries 1.5% of GDP or USD 2
billion in 1997.
· A malaria-stricken family spends over one quarter of its income on malaria
treatment. Families pay prevention costs and suffer loss of income from repeated
attacks.
· Complex emergencies and natural disasters increase malaria risk.
· Malaria is curable if promptly diagnosed and adequately treated.
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              Tuberculosis
· Tuberculosis (TB) each year kills 2 million people with 95% of deaths occurring in
developing countries. TB is the leading cause of death among the HIV positive.
· TB infection is increasing across the globe with a four-fold increase in several
African countries over the past decade and new outbreaks in Eastern Europe after
40 years of steady decline.27
· Over the next 20 years nearly one billion people will be newly infected, 200 million
people will get sick, and 35 million will die from TB.
· A person with infectious TB infects 10-15 people every year.
· TB affects the weakest and traps people in a cycle of poverty and disease. Most of
those affected are in the economically active population with women less likely to
be detected and treated.
· A highly effective cure exists and a course of treatment costs as little as USD 11.
· The emergence and spread of multi-drug resistant TB due to inappropriate
treatment or compliance with treatment prescriptions represents a global threat.
                                               
27 While recognising the scale of the TB problem in the countries of Eastern Europe in transition, the
focus of this initiative will be on developing countries.
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Annex 2
EC Health, AIDS and Population Portfolio
Poverty reduction has become the overarching aim of EC development policy with assistance
to health, HIV/AIDS and population programmes (or HAP) playing an increasingly important
role.  As a result, aid to these themes and sectors has grown continuously and from barely 1%
of total EC aid in 1986 now represents more than 8 %. The OECD average support to HAP is
around 5.5 % in 1998.
EC commitments to health, AIDS and population in 1998 amounted to well over Euro 700
million (figure 1) for more than 100 developing countries.
Between 1993 and 1997, 22% of HAP support in ACP countries was used for construction,
17% for technical assistance, 13% for equipment, 11% for consumables and 11% for human
and institutional development (figure 3). Since 1998 the shift towards sector wide approaches
in partnerships with Government, civil society and other donors has continued. Less funds are
channelled to construction and equipment, while the focus on human and institutional
development has significantly increased. Figure 7 shows EC commitments on HAP 1994 -
1998 for Asia, Latin-America, ACP countries and the Mediterranean.
The EC's HIV/AIDS policy and programmes have mainly supported poverty reduction
strategies through sustained cross-sectoral prevention efforts (53% of the activities financed
1987 – 1997 – figure 4) and primary health care (42% of the activities financed 1993 - 1997).
Overall accumulated EC commitments to HAP related activities in developing countries
between 1990 and 1998 amount to around Euro 3.4 billion. A forthcoming portfolio review
and overall evaluation (programmed for 2001) will define the nature of commitments,
countries/regions, partners, levels of interventions and type of budgetary instruments. Taken
together, EC and EU Member States now provide more than half of all development assistance
to health related programmes around the globe.
.
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Figure 1. Commitments to Health, AIDS and Population
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Figure 2. Evolution of type of expenditure and project focus in Health, HIV/AIDS and
Population interventions (1988-1992)
Type of Expenditure 1988-1992
Buildings
45%
Equipment
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Operating Cost 1%
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Contingencies 
10%
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7%
28
Project Focus 1988-1992
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Figure 3. Evolution of type of expenditure and project focus in Health, HIV/AIDS and
Population interventions (1993-1997)
Type of Expenditure 1993-1997
Consumables
11%
Support for NGOs
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5%
Studies 5%
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Project Focus 1993-1997
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11%
HIV/AIDS
15%
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Figure 4. Commitments to HIV/AIDS interventions (1987-1997)
Figure 5. Commitments to HIV/AIDS interventions by region (1987-1997)
Commitments by region 1987-1997
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Figure 6.  Commitments to HIV/AIDS interventions by partner type (1987-1997)
Figure 7. Overall EU Commitments to Health, AIDS and Population 1994 - 1998.
EC Commitments to
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Region Commitments Total28
Asia Euro 444.215 million
Latin America Euro 173.550  million
Mediterranean Euro 244.860 million
ACP (incl. South Africa) Euro 497.712 million
Overall Total Euro 1,359.9 million
COMMITMENTS THROUGH THE HIV/AIDS AND DEMOGRAPHY SPECIAL BUDGET
LINES (B7-6211, B7-6212 and B7-6310)
Region Amount Year
Euro 18.1 million 1995
Euro 21.9 million 1996
Euro 20.1 million 1997
Euro 23.9 million 1998
Euro 24.8 million 1999
All Developing Countries
(Euro 20 million 2000)
Overall Total Euro 108.8 million
                                               
28 First review prepared by DG DEV. This list does not include interventions funded through
other instruments such as budget aid (including structural adjustment), NGO co-financing, research,
refugee budget lines or ECHO nor does it include funding of health programming under PHARE or
TACIS.
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Annex 3
Summary of actions taken in follow-up to
the Commission Communication on increased solidarity to confront AIDS
in developing countries (com-98-407)
Adopted by the Commission on July 3 1998, this Communication provided the basis for a
European response to calls for more international solidarity with developing countries in
confronting HIV/AIDS, and in particular, calls for increased access to care for HIV/AIDS and
the need for HIV vaccines and microbicides for developing countries.
The Communication stressed the importance for the EU to build upon and strengthen existing
actions in support of affordable and effective targeted preventative interventions, and the need
to strengthen health care delivery systems in developing countries as a pre-requisite for
improved access to drugs, especially anti-retrovirals, for people with HIV/AIDS.
In addition, the Communication explored the potential for the creation of new solidarity
mechanisms, and examined the prospect of financing care, including anti-retrovirals, in
developing countries and the possibility of supporting accelerated development of vaccines
and microbicides.
In line with the priorities set in the Communication for additional and new EC efforts - in
addition to the existing substantive programmes of support for health, including HIV/AIDS, in
developing countries, a number of new initiatives were launched by the European Commission.
There is no doubt that these initiatives on improved access to care and development of
new vaccines and microbicides in the context of HIV/AIDS, form a useful basis for EC
work under the proposed programme for increased investment on communicable
diseases in developing countries.
Initiatives for the prevention of mother to child transmission
1. The EC supported a number of pilot projects in preventing mother-to-child
transmission of HIV/AIDS in developing countries. The projects included the careful
introduction of an essential package of treatment regimens for zero-positive pregnant
women.
2. Under the auspices of the EC and in co-operation with UNAIDS and the main other
actors in this field, the "Group of Ghent" - a think-tank of scientists and health
professionals - developed a public health strategy for mother-to-child interventions
and designed intervention packages to reduce mother-to child transmission as an
integral part of antenatal, obstetric and paediatric care. A pilot project based on the
strategy and intervention package has started in Burkina Faso.
3. Initiatives in support of the development and availability of an HIV/AIDS vaccine in
developing countries.
Initiatives to support vaccine development
1. At the initiative of the Directorate for Development a technical consultation on
making an AIDS vaccine available in developing countries: economic and
financing issues, was held in March 1999. The consultation prioritised actions to
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address barriers to vaccine development, identified areas where the European Union
has a comparative advantage, and led to the establishment of an Inter-Service HIV
Vaccine Task Team within the European Commission, lead by DG Development.
2. The Inter-Service HIV Vaccine Task Team includes representatives of Directorates
responsible for development, scientific research, industry and enterprise, the European
Investment Bank (EIB) and European Medicines Evaluation Agency (EMEA). The
Team has developed a comprehensive strategy and action plan.
3. The EC HIV vaccine strategy and programme of action includes the following key
elements: vaccine research and development; public health and economic research;
vaccine preparedness; policy dialogue; and intellectual property and regulatory issues.
Specific sponsored actions to date include:
1. Funding for the Eurovac cluster project, through the Commission’s Directorate for
Scientific Research Framework Programme. This three-year collaboration between
European research institutions and industry will identify potential candidate vaccines
for developing countries and develop new techniques for vaccine delivery and funding
of enabling projects for HIV vaccine development.
2. A programme of collaboration between the Commission’s Directorate for
Development and the World Bank on “willingness to pay” studies, in order to assess
the potential demand for an HIV vaccine in a range of developing countries, and on
modelling the potential public health impact and cost-effectiveness of an HIV vaccine
in different settings.
3. Directorate for Development financing of community preparedness research by the
South African AIDS Vaccine Initiative and the South African Medical Research
Council, on legal and ethical issues including community mobilisation and
participation in vaccine development and clinical trials.
Initiatives in support of the development and availability of microbicides
1. The EC commissioned and supervised a study into the market potential for vaginal
microbicides that could protect against STDs, including HIV.
2. Progress towards the development of microbicides effective against STD's, incl. HIV
has been fragmentary, mainly because the pharmaceutical industry lacks confidence
that such a market exists. Research carried out amongst 4000 individuals in Brazil, the
Ivory Coast, Egypt France, India, Kenya, the Philippines, Poland, South Africa,
Thailand and Venezuela. The results of the study show a great deal of interest from
women for such a product and that there is, without a doubt, a commercial - as well
as a moral - justification for further product development.
3. Furthermore, a call for proposals was launched with a specific thematic budget line
(year 2000) to support innovative programmes in the areas identified in the
Communication on increased solidarity.
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Annex 4
DG Research Investments into projects related to HIV, Malaria and TB
The international collaboration29 and life sciences30 programmes of DG Research are investing
in a complementary manner into research and development of vaccines and drugs against those
communicable diseases affecting the poorest most. Catalysed through the task force on
vaccines and viral diseases, the past years have witnessed a considerable increase of resources
devoted to this field. Moreover, research is successively moving from discovery into preclinical
and clinical validation phases. Recently, major integrated research consortia (“clusters”) have
been established under the life sciences programme.
INCO-DC / INCO-DEV
Under the 4th Framework Programme INCO DC (1994-1998), EC has been funding 154 health
related projects, involving some 119 research teams from 31 African countries, in a total
amount of Euro 80 million. Approximately two-third are directly linked to the priority diseases
HIV, TB and malaria. Research covered epidemiology, transmission and intervention
strategies, drug research as well as molecular and vaccine research. INCO supports the
European Malaria Vaccine Initiative (EMVI) and the African Malaria Vaccine Testing
Network (AMVTN).
Under the 5th Framework Programme INCO-DEV (1999-2002), Euro 10 million were
committed for vaccine research, and Euro 15 million could be allocated to drug and
diagnostics development (2000). A forthcoming call (2001) will be targeted at the three major
communicable diseases.
BIOMED / BIOTECH / Key Action Control of Infectious Diseases
The 4th Framework Programme programmes BIOMED/BIOTECH pursued different
strategies: BIOMED invested into European networking projects on HIV (Euro 13.7 million
for 31 projects) and TB (Euro 3.3 million for 7 projects).  BIOTECH gave support to
underpinning vaccine research (Euro 30 million for 34 projects) and to a limited number of
advanced vaccine research, including clinical trials on HIV, malaria and schistosomiasis (Euro
5.3 million 5 projects).
With the 5th Framework Programme, the Key Action Control of Infectious Diseases has
embraced a global view in its programme objectives. 40% of its currently committed budget
(total budget over 4 years is Euro 300 million) is on projects linked to the three major
communicable diseases. A novelty is the successful implementation of large cluster projects, in
particular for HIV, TB and malaria vaccines, as well as for TB drug development. So far, Euro
21.8 million have been committed for HIV, Euro 8.8 million on malaria and Euro 9.9 million
on TB research, with app. 2/3 of the budget being reserved for vaccine research and 1/3 for
drug development.
                                               
29 INCO-DC (International Co-operation Developing Countries) and INCO-DEV.
30 BIOTECH, BIOMED, Quality of Life “Key Action Control of Infectious Diseases”.
